Monte Rosa Therapeutics (NASDAQ:GLUE) CEO Sells $128,396.34 in Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) CEO Markus Warmuth sold 5,466 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $23.49, for a total transaction of $128,396.34. Following the completion of the transaction, the chief executive officer owned 618,937 shares of the company’s stock, valued at approximately $14,538,830.13. The trade was a 0.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Monte Rosa Therapeutics Trading Down 4.1%

Shares of GLUE opened at $24.28 on Monday. The company has a market cap of $1.58 billion, a price-to-earnings ratio of 75.88 and a beta of 1.60. The business’s fifty day simple moving average is $16.01 and its two-hundred day simple moving average is $9.81. Monte Rosa Therapeutics, Inc. has a 12 month low of $3.50 and a 12 month high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.06. Monte Rosa Therapeutics had a return on equity of 8.28% and a net margin of 11.54%.The firm had revenue of $12.77 million for the quarter, compared to the consensus estimate of $7.37 million. As a group, research analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.49 EPS for the current year.

Institutional Investors Weigh In On Monte Rosa Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GLUE. SG Americas Securities LLC bought a new position in Monte Rosa Therapeutics in the 4th quarter worth about $271,000. Wealth Enhancement Advisory Services LLC increased its holdings in Monte Rosa Therapeutics by 20.2% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,289 shares of the company’s stock worth $357,000 after purchasing an additional 3,746 shares during the period. GAMMA Investing LLC bought a new stake in Monte Rosa Therapeutics during the 4th quarter valued at $30,000. Vestal Point Capital LP purchased a new stake in shares of Monte Rosa Therapeutics in the 3rd quarter worth $5,928,000. Finally, Scientech Research LLC purchased a new stake in shares of Monte Rosa Therapeutics in the 3rd quarter worth $120,000. Institutional investors own 79.96% of the company’s stock.

Trending Headlines about Monte Rosa Therapeutics

Here are the key news stories impacting Monte Rosa Therapeutics this week:

• Positive Sentiment: Interim Phase I data showed MRT‑8102 produces deep NEK7 degradation and drove a large reduction in inflammation markers, which triggered a big intraday rally in the stock. GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
• Positive Sentiment: Early trial readouts reported ~85% CRP reduction (a key inflammation marker), reinforcing clinical promise for MRT‑8102 and sparking investor enthusiasm. Monte Rosa stock surges after positive data shows 85% CRP reduction
• Positive Sentiment: Analysts reacted to the clinical news with bullish moves — Guggenheim raised its PT to $34 and issued a Buy, and Wells Fargo raised its PT to $30 with an Overweight. These actions support upside from fundamentals if clinical progress continues. Benzinga
• Positive Sentiment: Zacks upgraded GLUE from Hold to Strong Buy amid the data-driven momentum, adding to short‑term buyer interest. Zacks.com upgrade
• Neutral Sentiment: Several market watchers flagged GLUE as a “stock on the move,” highlighting momentum and technical strength that could attract momentum traders. Monte Rosa Therapeutics (GLUE) is on the Move
• Negative Sentiment: Monte Rosa priced an underwritten public offering to raise roughly $300 million: 11,125,000 shares at $24.00 plus 1,375,000 pre‑funded warrants at $23.9999. The timing — immediately after a sharp rally — increases share supply and dilution risk, which likely weighed on the stock. Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Wedbush restated an “outperform” rating and set a $37.00 price target on shares of Monte Rosa Therapeutics in a report on Wednesday. Jefferies Financial Group reissued a “buy” rating and issued a $31.00 target price on shares of Monte Rosa Therapeutics in a research note on Wednesday. Guggenheim lifted their price target on shares of Monte Rosa Therapeutics from $16.00 to $34.00 and gave the stock a “buy” rating in a research note on Thursday. Zacks Research upgraded shares of Monte Rosa Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 6th. Finally, Wells Fargo & Company raised their price objective on shares of Monte Rosa Therapeutics from $22.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Monte Rosa Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $30.20.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.